By agreeing to buy LivaNova PLC's cardiac rhythm management business for $190m, China's MicroPort Scientific Corp. has bagged itself a good deal, considering the unit generates sales of around $250m a year.
CRM is the smallest of LivaNova's key businesses, the other two being cardiac surgery and neuromodulation. It recorded sales of $249m in 2016, accounting for around 21% of total sales,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?